文献速递免疫规划

单价C群脑膜炎球菌结合疫苗与四价ACWY群脑膜炎球菌结合疫苗加强免疫诱导的C群免疫原性、抗体持久性和记忆B细胞:一项随机对照试验

Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
PubMed 文献 · Vaccine · 2017-06-28

研究纳入10、12、15岁健康青少年,随机接受MenC-TT或MenACWY-TT加强免疫,比较MenC免疫应答。加强后1个月所有组MenC rSBA滴度均>24,000,1年时单价疫苗组GMT更高,非劣效未证实,但99.6%(462/464)参与者维持保护性rSBA滴度,两种疫苗均诱导记忆B细胞增加。

要点

  • 加强后1个月所有组MenC rSBA滴度均>24,000,IgG水平升高。
  • 加强后1年单价疫苗组MenC GMT高于四价疫苗组,非劣效未证实。
  • 462/464(99.6%)参与者维持保护性MenC rSBA滴度,两种疫苗均诱导记忆B细胞增加。

主要发现

  • 加强后1个月所有组MenC rSBA滴度均>24,000,MenC-PS特异性IgG水平升高。
  • 加强后1年单价疫苗组MenC GMT高于四价疫苗组,非劣效性未证实。
  • 462/464(99.6%)参与者维持保护性MenC rSBA滴度。
  • IgG以IgG1为主,IgG1和IgG2升高水平相似;两种疫苗均诱导循环MenC-PS特异性IgG和IgA记忆B细胞明显增加。
  • 加强后1个月至1年间,10岁组抗体衰减速率最高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adolescents are considered the key transmitters of meningococci in the population. Meningococcal serogroup C (MenC) antibody levels wane rapidly after MenC conjugate vaccination in young children, leaving adolescents with low antibody levels. In this study, we compared MenC immune responses after booster vaccination in adolescence with either tetanus toxoid conjugated MenC (MenC-TT) or MenACWY (MenACWY-TT) vaccine, and aimed to establish an optimal age for this booster. METHODS: Healthy 10-, 12-, and 15-year-olds, who received a single dose of MenC-TT vaccine in early childhood, were randomized to receive MenC-TT or MenACWY-TT vaccine. MenC serum bactericidal antibody (rSBA) titers, MenC polysaccharide (PS) specific IgG, IgG1 and IgG2 and MenC-specific IgG and IgA memory B-cells were determined before, one month and one year after the booster. Non-inferiority was tested by comparing geometric mean titers (GMTs) between vaccinees at one year. RESULTS: Of 501 participants, 464 (92.6%) were included in the 'according to protocol' cohort analysis. At one month, all participants developed high MenC rSBA titers (>24,000 in all groups) and MenC-PS-specific IgG levels. Non-inferiority was not demonstrated one year after the booster with higher MenC GMTs after the monovalent vaccine, but 462/464 (99.6%) participants maintained protective MenC rSBA titers. IgG levels mainly consisted of IgG1, but similar levels of increase were observed for IgG1 and IgG2. Both vaccines induced a clear increase in the number of circulating MenC-PS specific IgG and IgA memory B-cells. Between one month and one year, the highest antibody decay rate was observed in the 10-year-olds. CONCLUSION: Both MenC-TT and MenACWY-TT vaccines induced robust protective MenC immune responses after the booster vaccination, although non-inferiority could not be demonstrated for the MenACWY-TT vaccine after one year. Our results underline the importance of optimal timing of a meningococcal booster vaccination to protect against MenC disease in the long-term.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van Ravenhorst MB, van der Klis FRM, van Rooijen DM, et al. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial. Vaccine. 2017. PMID: 28668575. doi:10.1016/j.vaccine.2017.06.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。